Motus GI is on track to grow its Pure-Vu endoscopy system in 2021, according to CEO Tim Moran. He spoke on four value-creation drivers — reimbursement, product innovation, clinical data and strategic partnerships — in an earnings call transcribed by Seeking Alpha March 16.
The company recently reported a $19.3 million net loss in 2020 and a $4.4 million net loss in the fourth quarter, a slight improvement from 2019.
Five quotes from Mr. Moran on value-creation drivers and performance:
On reimbursement: “In the fourth quarter, we submitted an application to CMS for a new technology add-on payment. This program could provide reimbursement for Pure-Vu during inpatient colonoscopy. As part of this submission, we also applied for an ICD-10 code … [and] I am pleased to share that they recommended Pure-Vu to be considered for an ICD-10 code. … We also submitted an application for CMS’ transitional pass-through payment. This program could provide reimbursement for traditional outpatient procedures.”